RxDoctor Payments Data

Erica Brown

Adult Health · Cedar Rapids, IANPI 1922247808

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 11 manufacturers reported payments, led by Sumitomo Pharma America, Inc. at 26.3% of the total. 2025 is the largest year on record at $453, 8.9 times the $51 reported in 2021.

$599in general payments, 2019–2025

Across 24 payments — averaging $24.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$158
  • 180 Medical, Inc.$98
  • Urogen Pharma, Inc.$92
  • Astellas Pharma US Inc$51
  • Johnson & Johnson$44
  • Vertex$39
  • plus $117 from 5 others

What the payments were for

  • Food & beverage$599100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$599 in reported general payments places this provider in the 75th percentile of 77 adult health providers in Iowa.

See all adult health providers in Iowa

Medicare billing

Part B allowed, 2024
$21,378
Medicare patients
307
Services billed
427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron12$5,334
Tamsulosin Hcl105$1,222
Methenamine Hippurate14$754
Finasteride69$710
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst36$557
Testosterone Cypionate12$504
Cephalexin65$385
Oxybutynin Chloride ErOxybutynin Chloride28$323
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim44$213
Alfuzosin Hcl ErAlfuzosin Hcl12$200
Doxycycline Hyclate12$155
Ciprofloxacin Hcl46$150
Oxybutynin Chloride33$139
Naproxen53$127
Fluconazole11$79

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$51$5,33412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 77 adult health providers in Iowa.

Other adult health in Cedar Rapids

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →